|Dr. Georges Gemayel C.F.A., Ph.D.||Interim Pres & CEO and Exec. Chairperson||256.73k||N/A||1960|
|Mr. Brian Piekos||Chief Bus. Officer, CFO, Principal Accounting & Principal Financial Officer||549.73k||N/A||1976|
|Mr. Jason Patrick Meyenburg M.B.A., M.D.||Advisor||715.96k||N/A||1978|
|Mr. Patrick Truesdell||VP of Fin. & Controller||N/A||N/A||1981|
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Gemini Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.